De TrueDiscovery™-, TrueTarget™- en TrueSignature™-platforms bieden een geïntegreerde reeks onderzoeksdiensten die diepgaande biologische inzichten onthullen, van vroege ontdekking tot in de kliniek.
ZURRICH–(BUSINESS WIRE)– Biognosys, een leider in proteomics-oplossingen van de volgende generatie voor het ontdekken en ontwikkelen van geneesmiddelen, heeft vandaag de lancering aangekondigd van zijn uitgebreide reeks proteomics-platforms die farmaceutische en diagnostische klanten diepgaande biologische inzichten bieden in de gehele R&D-pijplijn, van ontdekking in een vroeg stadium tot klinische instellingen.
Biognosys biedt al meer dan een decennium een grote verscheidenheid aan op massaspectrometrie gebaseerde proteomics contractonderzoeksdiensten. Door zijn portfolio van onderzoekstoepassingen te organiseren en uit te breiden onder drie eigen platforms — TrueDiscovery™, TrueTarget™ en TrueSignature™ — maakt Biognosys het nu gemakkelijker voor zijn biofarmaceutische klanten om meerdere complementaire proteomics-oplossingen te integreren in hun volledige pijplijn voor medicijnontdekking en klinische ontwikkeling.
Biognosys Launches Expanded Suite of Proteomics Platforms to Support Drug Research and Development
The TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms provide an integrated suite of research services that reveal deep biological insights from early stage discovery to the clinic.
ZURICH–(BUSINESS WIRE)– Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the launch of its expanded suite of proteomics platforms that provide pharmaceutical and diagnostics customers with deep biological insights across the entire R&D pipeline, from early stage discovery to clinical settings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220303005059/en/
Biognosys has been offering a large variety of mass spectrometry-based proteomics contract research services for more than a decade. By organizing and expanding its portfolio of research applications under three proprietary platforms — TrueDiscovery™, TrueTarget™, and TrueSignature™ — Biognosys now makes it easier for its biopharma customers to integrate multiple complementary proteomics solutions across their entire drug discovery and clinical development pipeline.
TrueSignature is a significant enhancement of the company’s portfolio. Through this platform, Biognosys develops and runs customizable precision proteomics biomarker panels. TrueDiscovery and TrueTarget build on Biognosys’ existing key offerings for biomarker discovery and drug target identification respectively.
Kristina Beeler, PhD, Chief Business Officer of Biognosys, states: “By consolidating and expanding our research applications into the TrueDiscovery, TrueTarget, and TrueSignature proteomics platforms, we uniquely equip our collaborators and customers with transformative insights to propel their research and development journey from discovery to clinic.”
Karel Novy, PhD, Chief Operating Officer of Biognosys, comments: “The launch of the TrueDiscovery, TrueTarget, and TrueSignature platforms is a testimony of our commitment to provide customers with high-quality mass spectrometry solutions that are applicable and transferable throughout every stage of drug development.”
TrueDiscovery: unbiased biological insights from tissue and biofluids
Biognosys’ TrueDiscovery platform provides an integrated proteomics-based approach to disease biology profiling, mechanisms of action studies, and novel biomarker discovery.
TrueDiscovery is powered by hyper reaction monitoring (HRM) mass spectrometry, an advanced data-independent acquisition (DIA)-based protein quantification technology co-invented and patented by Biognosys.
TrueDiscovery is the only proteomics platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms. The platform achieves a depth of up to 13,000 proteins in tissue and 5,000 proteins in biofluids, and analyzes tens of thousands of peptide-level data points for enhanced specificity. The generated data are highly reproducible and easily transferrable to clinical assays. Studies using TrueDiscovery are performed in Biognosys’ GLP certified and GCP compliant lab facility. For more information, visit truediscovery.bio.
TrueTarget: novel drug target identification and validation
Biognosys’ TrueTarget proteomics platform addresses the most pressing challenges in early drug discovery: target identification and validation. By identifying on- and off-target binding effects across the proteome, TrueTarget can help accelerate and de-risk the early stages of drug development.
TrueTarget is powered by limited proteolysis-coupled mass spectrometry (LiP-MS), a proprietary, patented chemoproteomics technology co-developed by Biognosys. TrueTarget is the only tool to probe structural changes across the complete proteome with peptide-level resolution, providing unique insights into compound binding and target identification. The platform elucidates mechanisms of action and reveals unanticipated toxicities. For more information, visit truetarget.bio.
TrueSignature: custom panels for absolute protein quantification
Biognosys’ TrueSignature platform provides high-precision customizable proteomics panels for pharmacodynamic readouts and clinical biomarker monitoring — a significant addition to the company’s discovery proteomics services.
Parallel reaction monitoring mass-spectrometry powers the platform, allowing complete customization and independence from affinity-based recognition and reagent availability. The TrueSignature panels offer an unprecedented level of multiplexing, enabling the simultaneous absolute quantification of up to 100 proteins with industry-leading throughput.
TrueSignature panels can be developed within weeks and are available both as a standalone solution or an integrated solution, in which insights from TrueDiscovery studies guide the choice of proteins in the custom panels. This platform was built through a series of successful pilot projects with multiple collaborators and was already deployed in clinical trial settings. The TrueSignature offering will be available under GLP and GCP in the near future. For more information, visit truesignature.bio.
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions, and making them widely available for pharmaceutical and biotechnology researchers, and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut™. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com.
Head of Marketing and Communications
Phone +41 (0) 79 571 09 21